Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 13/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680654 | 0.94 | ENPP2 (0.48) | ENPP2MAPTMAPK1NPC1RAB9A | |
| SCHEMBL4787570 | 0.89 | ALDH1A1 (0.40) | ENPP2KMT2AMAPTMAPK1HTT | |
| SCHEMBL4686057 | 0.89 | SMN1; SMN2 (0.37) | ENPP2KMT2AMAPTMAPK1KDM4E | |
| SCHEMBL4678388 | 0.86 | KDM4E (0.36) | ENPP2MAPK1KDM4EPKM | |
| SCHEMBL4742831 | 0.85 | NPC1 (0.38) | MAPTNPC1RAB9A | |
| SCHEMBL4684410 | 0.81 | ALDH1A1 (0.37) | ENPP2KMT2AMAPTMAPK1HTT | |
| SCHEMBL4683309 | 0.78 | ALDH1A1 (0.42) | ENPP2KMT2AMAPTMAPK1HTT | |
| SCHEMBL4684196 | 0.77 | BDKRB1 (0.34) | ENPP2KMT2AMAPTNPC1RAB9A | |
| SCHEMBL4684412 | 0.76 | ENPP2 (0.42) | ENPP2KMT2AMAPTMAPK1HTT | |
| SCHEMBL4680646 | 0.76 | ENPP2 (0.38) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437349-B9 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1437349-B1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2007-08-15 | — | — | EP | disclosed |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | ENPP2 3361/4885KMT2A 3921/4885MAPT 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.